Clinical-stage biopharmaceutical company CymaBay Therapeutics (NASDAQ: CBAY) has closed an underwritten public offering of 9,200,000 shares of its common stock, which includes an additional 1,200,000 shares pursuant to the full exercise of the over-allotment option. According to the update, CymaBay Therapeutics realized gross proceeds of approximately $115 million resulting from the shares sold at the public offering price of $12.50 per share. The company anticipates using the proceeds to fund ongoing development of seladelpar, as well as for working capital and general corporate purposes. ROTH Capital Partners acted as co-manager for the transaction.
To view the full press release, visit http://nnw.fm/Vj4dU
About CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay’s lead development candidate, seladelpar, is a potent, selective and orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently enrolling patients in a global, phase 3 registration study of seladelpar for PBC. This study is a 52-week, placEbo-coNtrolled, randomized, pHAse 3 study to evaluate the safety aNd effiCacy of sEladelpar (“ENHANCE”) in patients with PBC. CymaBay is also conducting a Phase 2b proof-of-concept study of seladelpar in patients with NASH. For more information, visit the company’s website at www.CymaBay.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com